Maravai LifeSciences Holdings, Inc. (MRVI) Stock Price & Analysis
Maravai LifeSciences Holdings, Inc. (MRVI) closed at USD 7.07 on Thursday, October 22, 2026, down 6.61% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 7.57; the Oct 22, 2026 session ranged USD 6.73–7.61 on volume of 3,920,278 shares. Market capitalization is $2.62B, with a 52-week range of USD 2.55–9.42 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MRVI.md
Key facts (MRVI)
- Last four reported quarters (through Jun 30, 2026): revenue $209M, net income -$77.4M (-37.1% margin), free cash flow -$35.8M (SEC filings).
- 2 of 80 tracked superinvestors hold MRVI (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $254K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.44 on a 1–5 scale) (9 analysts), mean target USD 8.5 (range 7–12).
- Total return with dividends: 1Y +103.2% vs S&P 500 +14.9%; 5Y -83.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.06, revenue estimate $43.6M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MRVI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $799M | $883M | $289M | $259M | $186M | $209M |
| Gross profit | $659M | $714M | $140M | $108M | $34.0M | — |
| Operating income | $555M | $574M | -$31.6M | -$236M | -$215M | -$117M |
| Net income | $182M | $220M | -$119M | -$145M | -$131M | -$77.4M |
| EPS (diluted) | $1.56 | $1.67 | -$0.90 | -$1.05 | -$0.90 | — |
| Free cash flow | $354M | $519M | $60.7M | -$22.2M | -$70.7M | -$35.8M |
| Gross margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.3% | — |
| Operating margin | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% | -56.1% |
| Net margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% | -37.1% |
| Revenue growth | +181.3% | +10.5% | -67.3% | -10.3% | -28.3% | — |
| Cash + short-term investments | $551M | $632M | $575M | $322M | $217M | — |
| Total debt | $531M | $527M | $524M | $296M | $292M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MRVI)
P/S 12.5x · EV/Sales 12.9x · P/B 12.8x · FCF yield -1.37% · Earnings yield -2.96% · Net debt $77.0M · EV $2.70B
Superinvestors (SEC 13F-HR, Q2 2026) (MRVI)
2 of 80 tracked investors hold MRVI. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Pacific Advisors | 0.07% | $5.5M | Unchanged | |
| First Eagle Investment | First Eagle Investment Management | 0.04% | $22.9M | Added +45.4% |
Insider sales (SEC Form 4, open-market, last ~7 months) (MRVI)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-09…2026-06-10 | Oreshack Kurt | General Counsel | 50,000 | $254K | 13% | Yes (adopted March 10, 2026) | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MRVI)
Consensus Buy (mean 2.44 on a 1–5 scale), 9 analysts; mean target USD 8.5 (low 7, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Target raised | Neutral | $2.5 → $8 |
| 2026-08-07 | Wells Fargo | Target raised | Overweight | $5.5 → $6.5 |
Total return (dividends reinvested) (MRVI)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +103.2% | -83.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +103.7% | -29.9% |
| Volatility (annualized) | 66.8% | 72.8% |
| Max drawdown | -29.6% (Jan 2026→Mar 2026) | -95.8% (Oct 2021→Apr 2025) |
MRVI revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| TriLink | $34.7M | 67.4% | +11.5% |
| Cygnus | $16.8M | 32.6% | +2.8% |
| Total revenue | $51.4M | 100% | — |
MRVI revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $31.3M | 60.8% | +2.1% |
| — UNITED STATES (part of North America) | $30.9M | 60.1% | +2.0% |
| — Latin and Central America (part of North America) | $386,000 | 0.8% | +88.3% |
| Europe, the Middle East and Africa | $10.5M | 20.3% | +24.5% |
| Asia Pacific | $9.3M | 18.1% | +14.2% |
| Total revenue | $51.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MRVI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Maravai Topco Holdings | “Our principal asset is our interest in Maravai Topco Holdings LLC ("Topco LLC"), and, accordingly, we depend on distributions from Topco LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement.” |
| Supplier | Glen Research | “Certain of our raw materials are sourced from a limited number of suppliers and some materials, including a proprietary DNA reagent, certain packaging materials, specific cell lines for Cygnus operations and certain raw materials used in our TriLink products, as well as those raw materials sold under the Glen Research brand, are sole sourced.” |
| Customer | FedEx (FDX) | “We ship a significant portion of our products to our customers through independent package delivery companies, such as World Courier, FedEx, UPS and DHL.” |
| Customer | UPS (UPS) | “We ship a significant portion of our products to our customers through independent package delivery companies, such as World Courier, FedEx, UPS and DHL.” |
| Partner | Topco | “•Our dependence, by virtue of our principal asset being our interest in Maravai Topco Holdings, LLC ("Topco LLC"), on distributions from Topco LLC to pay our taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the "Tax Receivable Agreement" or "TRA") together with various limitations and restrictions that impact Topco LLC's ability to make such distributions.” |
| Partner | GTCR | “We entered into a Director Nomination Agreement with GTCR that provides GTCR the right to nominate to the Board a number of designees equal to at least: (i) 100% of the total number of directors comprising the Board, so long as GTCR beneficially owns shares of Class A common stock and Class B common stock representing at least 40% of the total amount of shares of Class A common stock and Class B common stock it be…” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name MRVI in their SEC reports
| Relationship to MRVI | Company | Filing | Sentence |
|---|---|---|---|
| customer | CODEXIS, INC. (CDXS) | 10-K Mar 11, 2026 | “In January 2025, MAI assigned the MAI Supply Agreement to Maravai in connection with the sale of its related assets to Maravai.” |
MRVI customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 12.2% of revenue, per the company's 10-Q filed Aug 7, 2026. The company does not name it.
MRVI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.06 | $-0.05 | +20.1% | $43.6M | 9 |
| Next quarter (ends Dec 2026) | $-0.04 | $-0.03 | +43.2% | $50.9M | 8 |
| Current fiscal year (ends Dec 2026) | $-0.11 | $-0.11 | -5.4% | $211.8M | 9 |
| Next fiscal year (ends Dec 2027) | $-0.10 | $-0.09 | +9.7% | $224.9M | 9 |
Key Statistics (as of October 23, 2026 at 09:22 UTC)
| Price | USD 7.07 |
|---|---|
| Change | ▼ 6.61% (down) |
| Previous Close | USD 7.57 |
| Open | USD 7.44 |
| Day Range | USD 6.73 – 7.61 |
| 52-Week Range | USD 2.55 – 9.42 |
| Volume | 3,920,278 shares |
| Market Cap | $2.62B |
| Exchange | NMS |
Technical Analysis (MRVI)
Nexqual's technical model rates MRVI "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.39 (neutral) |
| vs SMA50 | Below (USD 7.31) |
| MACD | -0.06 (negative) |
Analyst Ratings (MRVI)
Wall Street analysts rate MRVI "Buy" based on 9 analysts, with a mean price target of USD 8.5 (range USD 7–12), per Nexqual as of October 23, 2026 at 09:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 8.5 |
| High Target | USD 12 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 4 / 0 |
Earnings (MRVI)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $43.56M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.02 vs est -0.04 ▲ beat |
| 2026-03-31 | USD 0.01 vs est -0.05 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.08 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financials & Fundamentals (MRVI)
| Total Revenue | $208.78M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.50% |
| Gross Margin | +35.71% |
| Operating Margin | -29.40% |
| Profit Margin | -37.07% |
| ROE | -33.05% |
| Debt / Equity | 0.61 |
| Current Ratio | 4.05 |
| Total Cash | $70.09M |
| Total Debt | $218.10M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$35.84M (-17.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financial Health Score (MRVI)
Nexqual rates Maravai LifeSciences Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:22 UTC.
| Growth | Critical — Revenue -28% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 36%, operating -29% (last 12 months) |
| Balance Sheet | Strong — $70M cash and investments vs $147M debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$36M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -33%, ROA -5.7% |
Ownership (MRVI)
| Insider Ownership | +7.23% |
|---|---|
| Institutional Ownership | +99.15% |
| Shares Outstanding | 148.99M |
| Float | 106.40M |
| Short % of Float | +10.99% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Leadership (MRVI)
Maravai LifeSciences Holdings, Inc. is led by Bernd Brust, CEO & Director, per Nexqual as of October 23, 2026 at 09:22 UTC.
| CEO & Director | Bernd Brust |
|---|---|
| Chairman of the Board | Robert Andrew Eckert |
| EVP & Chief Financial Officer | Rajesh J. Asorpota |
| Senior VP & Chief Scientific Officer | Chanfeng Zhao |
| Senior Director of Investor Relations | Debra Hart |
Major Backers & Investors (MRVI)
Notable institutional backers of Maravai LifeSciences Holdings, Inc. include GTCR, LLC, Braidwell LP , 12 West Capital Management Lp, according to Nexqual as of October 23, 2026 at 09:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GTCR, LLC | 13.52% |
| Braidwell LP | 5.84% |
| 12 West Capital Management Lp | 4.74% |
| Millennium Management | 4.37% |
| Ophir Asset Management Pty Ltd | 3.24% |
| Renaissance Technologies | 3.09% |
| First Eagle Investment Management, LLC | 2.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.69% |
| Vanguard Group | 3.55% |
| Deutsche Bank AG | 2.89% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
From Maravai LifeSciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We offer MockV® -based tools including the Minute Virus of Mice, the MockV® MVM kit and the CHO Retrovirus-like Particle, MockV® RVLP Kit, which are novel, proprietary viral clearance prediction tools that use a non-infectious "mock virus particle" mimicking the physicochemical properties of live virus that may be present endogenously in the drug substance or introduced during bioproduction.
- Our core offerings include mRNA, our proprietary CleanCap® mRNA capping and ModTail™ poly(A) tail modification technologies, long and short oligonucleotides, oligonucleotide inputs, nucleoside triphosphates, custom nucleic chemistry, and specialty enzymes.
- We provide our proprietary T7 enzyme for reducing double-stranded RNA ("dsRNA") during IVT.
- We are vertically integrated, and our enzymes are incorporated into our CleanScript™ mRNA production workflow.
Partnerships
- We support all customers with in-field and in-house technical support, alliance and program management and customer service.
- Regulatory requirements in both the United States and abroad are always evolving, and compliance with future laws may require significant investment to ensure compliance.
Legal & Regulatory Risks (Item 1A, quoted)
- Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing products and limit commercialization of any products that we may develop.
- Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code, and it is possible that changes in laws or certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our net operating loss and tax credit carryforwards.
- Risks Related to Laws and Regulations
- Our products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay or prevent commercialization of our products, thereby materially and adversely affecting our business, financial condition, results of operations, cash flows and prospects.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt